Compare Regeneron Pharmaceuticals Inc (REGN) vs S&P500 ETF (SPY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs S&P500 ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $745.44 (market cap $76.14B), while S&P500 ETF trades at $776.44 (market cap $821.54B). The key difference: S&P500 ETF is far larger — about 10.8× Regeneron Pharmaceuticals Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while S&P500 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and S&P500 ETF for 205 Days on average.
| REGN | SPY | |
|---|---|---|
Market Cap | $76.14B | $821.54B |
Volume | 500,239 | 40,070,358 |
Sector | Health | — |
52-Week High | $852.03 | $779.14 |
52-Week Low | $557.73 | $631.99 |
Typical Hold Time | 107 Days | 205 Days |
Enterprise Value | $70.85B | — |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.
The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.
SPY, the SPDR S&P 500 ETF, trades at $777.26, down 0.24% on the day, with a bullish technical signal from moving averages but a neutral reading from oscillators. The ETF is near its pivot point of $776, with immediate resistance at $779. Recent news highlights mixed sentiment, with some articles pointing to strong corporate earnings growth in 2026 but expected deceleration in 2027, while others discuss defensive positioning and valuation concerns.
The outlook for SPY is cautiously optimistic, supported by bullish technical trends and robust earnings growth projections for 2026. Key risks include potential profit growth slowdown in 2027, elevated market valuations, and macroeconomic headwinds such as rising Treasury yields. Investors should weigh the ETF's broad market exposure against these factors for long-term positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →
